Monday - December 23, 2024

Transglutaminase 2 (TG2) Inhibitors

2024-11-26

ALEXANDRIA, Virginia, Nov. 26 -- SITARI PHARMA, INC., Wilmington, Delaware has been assigned a patent (No. US 12152026 B2, initially filed Aug. 9, 2019) developed by five inventors David Campbell, La Jolla, California; Justin Chapman, La Jolla, California; Mui Cheung, Collegeville, Pennsylvania; Thomas R. Diraimondo, La Jolla, California; and Sergio G. Duron, La Jolla, California, for "Transglutaminase 2 (TG2) inhibitors." . . .

Information Request Form

Name:
Category that best fits the type of business or agency you are affiliated with:	Government Newspaper / Media Business Public Policy Individual / Student Educators
Company Name:
Email:
Phone:
State:

I'd like to have a copy of this article mailed to me.

To also receive a free sample of other Targeted News products check the appropriate boxes below.
Golf Handicap site (FairwayFiles.com)
Products marked with ** can be customized by keywords or areas of interest. If you select them please specify your keywords in the box below:

If we need to contact you please specify your preferred contact method. Have a representative contact me by phone
Have a representative contact me via email

Additonal questions or comments:

Click here for more information or a free trial

Existing Customer Login

Transglutaminase 2 (TG2) Inhibitors

Information Request Form

Copyright Targeted News Service 2024